- Home
- NWFL vs CTNM Comparison
NWFL vs CTNM Comparison
Compare NWFL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWFL
- CTNM
- Stock Information
- Founded
- NWFL 1870
- CTNM 2009
- Country
- NWFL United States
- CTNM United States
- Employees
- NWFL N/A
- CTNM N/A
- Industry
- NWFL Major Banks
- CTNM
- Sector
- NWFL Finance
- CTNM
- Exchange
- NWFL Nasdaq
- CTNM Nasdaq
- Market Cap
- NWFL 205.5M
- CTNM 199.3M
- IPO Year
- NWFL 1998
- CTNM 2024
- Fundamental
- Price
- NWFL $24.82
- CTNM $7.14
- Analyst Decision
- NWFL Buy
- CTNM Strong Buy
- Analyst Count
- NWFL 2
- CTNM 5
- Target Price
- NWFL $29.50
- CTNM $24.80
- AVG Volume (30 Days)
- NWFL 10.3K
- CTNM 44.8K
- Earning Date
- NWFL 04-21-2025
- CTNM 03-06-2025
- Dividend Yield
- NWFL 4.95%
- CTNM N/A
- EPS Growth
- NWFL N/A
- CTNM N/A
- EPS
- NWFL N/A
- CTNM N/A
- Revenue
- NWFL $48,367,000.00
- CTNM N/A
- Revenue This Year
- NWFL $78.94
- CTNM N/A
- Revenue Next Year
- NWFL $7.21
- CTNM $108.33
- P/E Ratio
- NWFL N/A
- CTNM N/A
- Revenue Growth
- NWFL N/A
- CTNM N/A
- 52 Week Low
- NWFL $23.50
- CTNM $5.92
- 52 Week High
- NWFL $34.50
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- NWFL 40.89
- CTNM N/A
- Support Level
- NWFL $24.75
- CTNM N/A
- Resistance Level
- NWFL $25.36
- CTNM N/A
- Average True Range (ATR)
- NWFL 0.42
- CTNM 0.00
- MACD
- NWFL -0.02
- CTNM 0.00
- Stochastic Oscillator
- NWFL 7.21
- CTNM 0.00
About NWFL Norwood Financial Corp.
Norwood Financial Corp is a U.S.-based bank holding company. It offers various personal and business credit services, trust and investment products, and real estate settlement services to consumers, businesses, nonprofit organizations, and municipalities in each of the communities that the bank serves. The bank also manages automated teller machines at its branch location. It serves the Pennsylvanian counties of Wayne, Pike, Monroe, and Lackawanna, as well as Susquehanna County.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.